| Name | Genus |
|---|---|
| Epic | GNS |
| Isin | GB0002074580 |
| Index | UK250 UK350 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 1,802.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £1,189.95 | Debt ratio | n/a |
| Shares in issue | 66.03 | Debt-to-equity ratio | n/a |
| P/E ratio | 25.2 | Assets / equity ratio | n/a |
| Total dividends per share | 32.00p | Price to book value | n/a |
| Dividend yield | 1.9 | ROCE | 3.38 |
| Dividend cover | 2.05 | EPS growth | -23 |
| Earning per share | 12 | 52-week high / low | 1,424.00p / 2,354.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| Final | 2024-11-07 | 2024-12-06 | 21.70p |
| Interim | 2024-02-29 | 2024-03-28 | 10.30p |
| Final | 2023-11-09 | 2023-12-08 | 21.70p |
| Interim | 2023-03-02 | 2023-03-30 | 10.30p |
| Final | 2022-11-17 | 2022-12-09 | 21.70p |
| Interim | 2022-03-03 | 2022-03-31 | 10.30p |
| Final | 2021-11-18 | 2021-12-10 | 21.70p |
| Interim | 2021-03-04 | 2021-04-01 | 10.30p |
| Final | 2020-11-19 | 2020-12-11 | 19.70p |
| Company name | Genus |
|---|---|
| Address | Matrix House, Basing View, Basingstoke, Hampshire, United Kingdom, RG21 4DZ |
| Telephone | +44 (0) 1256 347 100 |
| Website | http://www.genusplc.com |
| Director | Position |
|---|---|
| Mr Jorgen Kokke | CEO |
| Mr Alison Henriksen | CFO |
| Dr Ralph Heuser | Non-Executive Director |
| Mr Iain Ferguson | Non-Executive Chairman |
| Mrs Lesley Knox | Senior Independent Director |
| Ms Lysanne Gray | Independent Non-Executive Director |
| Professor Jason Chin | Independent Non-Executive Director |
| Mr Dan Hartley | General Counsel and Company Secretary |
| Assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Reporting date | 30/06/24 | 30/06/23 | 30/06/22 |
| Intangible asssets and goodwill | 175.7 | 174 | 183 |
| Investments and other non-current assets | 61.6 | 62.3 | 41.2 |
| Total non-current assets | 757.8 | 748.5 | 760.4 |
| Inventory / work in progress | 57.1 | 61.3 | 50.9 |
| Trade and other receivables | 137.3 | 136.1 | 133.5 |
| Cash and equivalents | 42.5 | 36.3 | 38.8 |
| Other current assets and asset held for resale | 34.2 | 25.3 | 34.3 |
| Total of all assets | 1028.9 | 1007.5 | 1017.9 |
| Liabilities £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Short term liabilities | 150.6 | 147.2 | 151.3 |
| Long term liabilities | 334.4 | 293.1 | 294.5 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 485 | 440.3 | 445.8 |
| Net assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net assets | 543.9 | 567.2 | 572.1 |
| Equity £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Share capital | 6.6 | 6.6 | 6.6 |
| Minority interests | -4.3 | -7.7 | -6.4 |
| Retained earnings | 351.2 | 360.6 | 340.6 |
| Share premium account | 179.1 | 179.1 | 179.1 |
| Total equity | 543.9 | 567.2 | 572.1 |
| Income £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | 6.4 | 40.5 | 49.4 |
| Pre-tax profit | 5.5 | 39.4 | 48.4 |